AL-ADTRAN
Adtran today announced that this month marks the 75th anniversary of Oscilloquartz. Founded in 1949, Oscilloquartz has evolved into a global leader in PNT network timing technology, setting numerous industry benchmarks throughout its history. The company offers precision synchronization solutions that empower customers to overcome timing challenges in sectors from telecoms to critical defense infrastructure. Over the years, Oscilloquartz has consistently led the way with groundbreaking achievements, such as introducing the industry’s first optical cesium atomic clocks with optical pumping technology, which provide unparalleled accuracy and reliability. This month also commemorates 10 years since Oscilloquartz was acquired by ADVA, now part of Adtran, helping it expand its portfolio of cost-effective timing technologies and establish the leading assured PNT platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523252321/en/
Adtran’s Oscilloquartz timing technology is playing a key role in helping organizations strengthen critical network infrastructure. (Photo: Business Wire)
“Celebrating 75 years of Oscilloquartz, alongside a decade since our integration into the Adtran family, represents a remarkable achievement. The dual anniversary highlights our enduring commitment to timing innovation and quality. Throughout these decades, we’ve navigated the evolving landscape from frequency solutions for legacy SONET/SDH to highly accurate frequency and time solutions for packet-based networks. Our dedication has enabled us to offer scalable technology that ensures robust timing, with or without satellite signals,” said Gil Biran, GM of Oscilloquartz, Adtran. “From pioneering the integration of synchronization delivery and assurance to bringing timing closer to end applications through our compact, low-power devices, including our latest family of OSAinside™ products, our portfolio has consistently addressed our customers’ key challenges. More recently, the introduction of the first commercial optical cesium atomic clocks was another major leap, significantly enhancing the precision and stability of network timing while substantially extending lifespan.”
Since its inception, Oscilloquartz has led the field in network synchronization, setting standards with the industry’s first commercial magnetic cesium atomic clock in 1966 and spearheading telecoms timing solutions in 1978. In 1982, it transformed the market by introducing the first high-performance quartz oscillators and resonators, which played a key role in developing the European Digital Cesium Standard in 1988. After its acquisition in 2014, Oscilloquartz expanded its global presence, with leading service providers adopting its products. It also provided customized solutions across metrology, finance and national defense sectors. Its leadership in cesium clock technology won support for its R&D initiatives from the European Space Agency. Continuing its legacy of innovation, Oscilloquartz recently enhanced the resiliency of GPS/GNSS systems with its Iridium®-based Satellite Time and Location (STL) technology solutions, leveraging low-Earth orbit satellite signals for more reliable, secure synchronization even in challenging environments.
“This historic anniversary is a moment to appreciate Oscilloquartz’s incredible journey, from its initial project at the astronomical observatory in Neuchâtel 70 years ago to the forefront of timing technology today,” commented Christoph Glingener, CTO of Adtran. “Over the last decade, the integration with ADVA and then Adtran has enriched Oscilloquartz’s offerings through the combined expertise of our teams. This era saw the debut of compact and cost-effective Oscilloquartz synchronization devices, delivering unmatched precision at the network edge. Its core grandmasters set new industry benchmarks with their 10GbE support and hardware timestamping. Together with Oscilloquartz’s optical atomic cesium clocks, they create a SePRTC+, guaranteeing accurate, reliable timing even during GNSS disruptions for up to 100 days. This combination of the industry’s most scalable family of grandmasters based on zero-trust architecture, coupled with optical pumping technology, sets Oscilloquartz apart today. As part of the Adtran family, Oscilloquartz will continue its legacy of excellence, keeping customers at the forefront of synchronization technology.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523252321/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
